Share Price and Basic Stock Data
Last Updated: December 4, 2025, 2:27 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemiesynth (Vapi) Ltd operates within the organic chemicals sector, focusing on various specialty chemicals. The company’s reported sales for the fiscal year ending March 2025 stood at ₹18.89 Cr, a slight recovery from ₹16.43 Cr in March 2024. However, this was a decline from the peak sales of ₹30.18 Cr in March 2022. Quarterly sales demonstrated volatility, with the latest quarter ending September 2023 recording ₹4.37 Cr, down from ₹7.12 Cr in December 2022. The total revenue from operations for the trailing twelve months (TTM) reached ₹21.40 Cr, indicating some resilience amid fluctuating quarterly performances. The company’s operating profit margin (OPM) for the most recent quarter was 2.77%, which is significantly lower than the sector average of approximately 10-15%. This inconsistent revenue trajectory highlights a need for strategic focus on market positioning and operational efficiency to enhance revenue stability.
Profitability and Efficiency Metrics
The profitability of Chemiesynth (Vapi) Ltd has faced challenges, as evidenced by a reported net profit of -₹1.18 Cr for the fiscal year ending March 2025. This contrasts with a net profit of ₹0.56 Cr in March 2023, showcasing a downward trend in profitability. The operating profit for the last quarter was marginally positive at ₹0.19 Cr, with a corresponding OPM of 2.77%. The interest coverage ratio stood at 2.75x, indicating that earnings are sufficient to cover interest obligations, but this remains low compared to the typical sector benchmark of above 3x. The return on equity (ROE) was reported at 0.99%, reflecting underperformance relative to sector norms, which generally exceed 10%. The company’s cash conversion cycle of 21.04 days and the inventory turnover ratio of 7.20x suggest that while inventory management is relatively efficient, overall profitability metrics need significant improvement to align with industry expectations.
Balance Sheet Strength and Financial Ratios
Chemiesynth’s balance sheet reveals a total debt of ₹15.21 Cr against reserves of ₹7.01 Cr, resulting in a debt-to-equity ratio of 1.37x. This ratio indicates a high reliance on debt financing, which poses risks, particularly in uncertain economic conditions. The company reported total assets of ₹32.19 Cr, with fixed assets valued at ₹25.83 Cr, indicating a substantial investment in long-term assets. The current ratio was recorded at 0.46x, below the ideal benchmark of 1.0, suggesting potential liquidity issues. The book value per share stood at ₹35.77, providing a cushion against the current market price of ₹37.6, which reflects a price-to-book value ratio of 0.95x. This valuation suggests that the company is trading at a discount relative to its book value, indicating a lack of investor confidence in its growth prospects. Overall, while the balance sheet shows some strengths in asset management, the high debt levels and liquidity concerns warrant careful scrutiny.
Shareholding Pattern and Investor Confidence
The shareholding structure of Chemiesynth (Vapi) Ltd reveals that promoters hold a significant 62.35% stake, indicating strong control over the company. This stable promoter holding could provide some assurance to investors regarding the alignment of management interests with shareholder value. Public ownership stands at 37.66%, with a total of 524 shareholders, reflecting a modest level of retail participation. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises concerns about the broader market confidence in the company’s prospects. The trend of consistent promoter holdings, alongside the slight fluctuation in public shareholding, may impact investor sentiment, particularly as the company continues to report losses. The lack of institutional backing often leads to heightened volatility in stock performance and can deter potential long-term investors looking for stability.
Outlook, Risks, and Final Insight
The outlook for Chemiesynth (Vapi) Ltd hinges on its ability to stabilize revenue and improve profitability metrics. Key risks include high debt levels and ongoing operational inefficiencies that could hinder financial performance. The company’s reliance on debt financing poses a significant risk, particularly during economic downturns, which could lead to liquidity challenges. Additionally, the volatility in revenue and profitability metrics suggests that the company must focus on enhancing operational efficiency and cost management to drive sustainable growth. On the positive side, the substantial promoter holding provides a level of stability that could be leveraged for strategic decision-making. If Chemiesynth can successfully implement operational improvements and manage its debt, it may improve its financial standing and attract institutional investors. However, without significant changes in strategy and performance, the company risks continued underperformance in a competitive sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 91.3 Cr. | 256 | 456/243 | 212 | 392 | 0.04 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,572 Cr. | 9,552 | 14,250/8,150 | 54.8 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 34.2 Cr. | 114 | 329/109 | 16.9 | 26.9 | 0.88 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 32.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 295 Cr. | 369 | 435/163 | 16.4 | 108 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,682.75 Cr | 1,536.78 | 64.85 | 334.84 | 0.40% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.43 | 7.12 | 4.85 | 4.39 | 4.37 | 3.22 | 4.45 | 2.85 | 5.47 | 3.88 | 6.68 | 3.97 | 6.87 |
| Expenses | 3.94 | 5.78 | 3.89 | 4.48 | 3.00 | 3.31 | 4.10 | 2.66 | 4.51 | 3.65 | 5.87 | 3.79 | 6.68 |
| Operating Profit | 0.49 | 1.34 | 0.96 | -0.09 | 1.37 | -0.09 | 0.35 | 0.19 | 0.96 | 0.23 | 0.81 | 0.18 | 0.19 |
| OPM % | 11.06% | 18.82% | 19.79% | -2.05% | 31.35% | -2.80% | 7.87% | 6.67% | 17.55% | 5.93% | 12.13% | 4.53% | 2.77% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Interest | 0.16 | 0.15 | 0.16 | 0.12 | 0.21 | 0.11 | 0.26 | 0.09 | 0.17 | 0.34 | 0.20 | 0.25 | 0.27 |
| Depreciation | 0.27 | 0.30 | 0.33 | 0.30 | 0.32 | 0.32 | 0.36 | 0.34 | 0.38 | 0.36 | 0.33 | 0.39 | 0.36 |
| Profit before tax | 0.06 | 0.89 | 0.47 | -0.51 | 0.84 | -0.52 | -0.26 | -0.24 | 0.41 | -0.47 | 0.29 | -0.46 | -0.44 |
| Tax % | 0.00% | 5.62% | 44.68% | 0.00% | 0.00% | 0.00% | -23.08% | 0.00% | 0.00% | 0.00% | 34.48% | 0.00% | 0.00% |
| Net Profit | 0.06 | 0.84 | 0.26 | -0.51 | 0.85 | -0.52 | -0.20 | -0.24 | 0.42 | -0.47 | 0.19 | -0.46 | -0.44 |
| EPS in Rs | 0.20 | 2.74 | 0.85 | -1.66 | 2.77 | -1.69 | -0.65 | -0.78 | 1.37 | -1.53 | 0.62 | -1.50 | -1.43 |
Last Updated: December 27, 2025, 2:04 pm
Below is a detailed analysis of the quarterly data for Chemiesynth (Vapi) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 6.87 Cr.. The value appears strong and on an upward trend. It has increased from 3.97 Cr. (Jun 2025) to 6.87 Cr., marking an increase of 2.90 Cr..
- For Expenses, as of Sep 2025, the value is 6.68 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.79 Cr. (Jun 2025) to 6.68 Cr., marking an increase of 2.89 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Jun 2025) to 0.19 Cr., marking an increase of 0.01 Cr..
- For OPM %, as of Sep 2025, the value is 2.77%. The value appears to be declining and may need further review. It has decreased from 4.53% (Jun 2025) to 2.77%, marking a decrease of 1.76%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.25 Cr. (Jun 2025) to 0.27 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.36 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.39 Cr. (Jun 2025) to 0.36 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.44 Cr.. The value appears strong and on an upward trend. It has increased from -0.46 Cr. (Jun 2025) to -0.44 Cr., marking an increase of 0.02 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.44 Cr.. The value appears strong and on an upward trend. It has increased from -0.46 Cr. (Jun 2025) to -0.44 Cr., marking an increase of 0.02 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.43. The value appears strong and on an upward trend. It has increased from -1.50 (Jun 2025) to -1.43, marking an increase of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.63 | 11.13 | 5.12 | 3.09 | 13.32 | 11.20 | 14.56 | 19.90 | 30.18 | 20.94 | 16.43 | 18.89 | 21.40 |
| Expenses | 9.10 | 11.55 | 5.26 | 3.17 | 12.67 | 9.26 | 12.27 | 14.32 | 25.71 | 18.37 | 14.88 | 16.68 | 19.99 |
| Operating Profit | 0.53 | -0.42 | -0.14 | -0.08 | 0.65 | 1.94 | 2.29 | 5.58 | 4.47 | 2.57 | 1.55 | 2.21 | 1.41 |
| OPM % | 5.50% | -3.77% | -2.73% | -2.59% | 4.88% | 17.32% | 15.73% | 28.04% | 14.81% | 12.27% | 9.43% | 11.70% | 6.59% |
| Other Income | 0.13 | 0.02 | 0.03 | 0.27 | 0.46 | 0.06 | 0.12 | 0.02 | 0.94 | 0.00 | 0.01 | 0.01 | 0.01 |
| Interest | 0.30 | 0.29 | 0.23 | 0.19 | 0.19 | 0.09 | 0.28 | 0.48 | 0.50 | 0.59 | 0.71 | 0.83 | 1.06 |
| Depreciation | 0.25 | 0.28 | 0.20 | 0.18 | 0.52 | 0.46 | 0.55 | 0.78 | 1.05 | 1.17 | 1.30 | 1.40 | 1.44 |
| Profit before tax | 0.11 | -0.97 | -0.54 | -0.18 | 0.40 | 1.45 | 1.58 | 4.34 | 3.86 | 0.81 | -0.45 | -0.01 | -1.08 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.31% | 17.09% | 17.74% | 29.79% | 32.10% | -13.33% | 1,000.00% | |
| Net Profit | 0.11 | -0.97 | -0.54 | -0.18 | 0.39 | 1.17 | 1.31 | 3.56 | 2.72 | 0.56 | -0.39 | -0.11 | -1.18 |
| EPS in Rs | 0.36 | -3.16 | -1.76 | -0.59 | 1.27 | 3.81 | 4.27 | 11.60 | 8.86 | 1.82 | -1.27 | -0.36 | -3.84 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -981.82% | 44.33% | 66.67% | 316.67% | 200.00% | 11.97% | 171.76% | -23.60% | -79.41% | -169.64% | 71.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1026.15% | 22.34% | 250.00% | -116.67% | -188.03% | 159.79% | -195.35% | -55.82% | -90.23% | 241.44% |
Chemiesynth (Vapi) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -14% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 0% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 10, 2025, 4:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 | 3.07 |
| Reserves | 0.70 | -0.28 | -0.82 | -1.05 | -0.66 | 0.52 | 1.83 | 5.39 | 8.10 | 8.66 | 8.27 | 7.91 | 7.01 |
| Borrowings | 6.46 | 6.70 | 8.17 | 8.02 | 8.01 | 7.69 | 9.73 | 10.86 | 11.60 | 13.63 | 15.54 | 15.02 | 15.21 |
| Other Liabilities | 3.00 | 2.74 | 1.27 | 1.58 | 1.48 | 3.59 | 3.18 | 7.55 | 6.86 | 5.65 | 4.49 | 6.19 | 7.27 |
| Total Liabilities | 13.23 | 12.23 | 11.69 | 11.62 | 11.90 | 14.87 | 17.81 | 26.87 | 29.63 | 31.01 | 31.37 | 32.19 | 32.56 |
| Fixed Assets | 10.41 | 10.09 | 9.98 | 9.71 | 9.62 | 10.69 | 12.31 | 20.39 | 22.38 | 24.51 | 25.08 | 25.83 | 27.38 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 1.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.82 | 2.14 | 1.71 | 1.91 | 2.28 | 3.94 | 4.16 | 6.48 | 7.25 | 6.50 | 6.29 | 6.36 | 5.18 |
| Total Assets | 13.23 | 12.23 | 11.69 | 11.62 | 11.90 | 14.87 | 17.81 | 26.87 | 29.63 | 31.01 | 31.37 | 32.19 | 32.56 |
Below is a detailed analysis of the balance sheet data for Chemiesynth (Vapi) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.07 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.07 Cr..
- For Reserves, as of Sep 2025, the value is 7.01 Cr.. The value appears to be declining and may need further review. It has decreased from 7.91 Cr. (Mar 2025) to 7.01 Cr., marking a decrease of 0.90 Cr..
- For Borrowings, as of Sep 2025, the value is 15.21 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 15.02 Cr. (Mar 2025) to 15.21 Cr., marking an increase of 0.19 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.19 Cr. (Mar 2025) to 7.27 Cr., marking an increase of 1.08 Cr..
- For Total Liabilities, as of Sep 2025, the value is 32.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.19 Cr. (Mar 2025) to 32.56 Cr., marking an increase of 0.37 Cr..
- For Fixed Assets, as of Sep 2025, the value is 27.38 Cr.. The value appears strong and on an upward trend. It has increased from 25.83 Cr. (Mar 2025) to 27.38 Cr., marking an increase of 1.55 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5.18 Cr.. The value appears to be declining and may need further review. It has decreased from 6.36 Cr. (Mar 2025) to 5.18 Cr., marking a decrease of 1.18 Cr..
- For Total Assets, as of Sep 2025, the value is 32.56 Cr.. The value appears strong and on an upward trend. It has increased from 32.19 Cr. (Mar 2025) to 32.56 Cr., marking an increase of 0.37 Cr..
However, the Borrowings (15.21 Cr.) are higher than the Reserves (7.01 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.93 | -7.12 | -8.31 | -8.10 | -7.36 | -5.75 | -7.44 | -5.28 | -7.13 | -11.06 | -13.99 | -12.81 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.51 | 26.89 | 31.37 | 24.81 | 27.13 | 55.08 | 39.86 | 67.86 | 41.60 | 47.24 | 47.10 | 55.07 |
| Inventory Days | 126.69 | 44.60 | 136.35 | 580.41 | 16.18 | 231.23 | 217.06 | 165.17 | 80.99 | 200.09 | 386.19 | 167.61 |
| Days Payable | 156.86 | 126.75 | 159.43 | 741.97 | 43.60 | 605.79 | 366.21 | 695.35 | 159.36 | 200.78 | 111.85 | 201.64 |
| Cash Conversion Cycle | -17.66 | -55.26 | 8.29 | -136.75 | -0.29 | -319.48 | -109.29 | -462.31 | -36.77 | 46.55 | 321.44 | 21.04 |
| Working Capital Days | -48.89 | -53.78 | -47.76 | -103.95 | -9.04 | -28.68 | -60.92 | -65.85 | -49.83 | -65.89 | -105.08 | -122.12 |
| ROCE % | 3.04% | -6.90% | -3.21% | -2.44% | 5.28% | 13.73% | 13.89% | 28.39% | 16.35% | 5.82% | 1.00% | 3.10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Diluted EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Cash EPS (Rs.) | 4.22 | 2.97 | 5.61 | 12.28 | 14.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Revenue From Operations / Share (Rs.) | 61.52 | 53.53 | 68.21 | 98.32 | 64.81 |
| PBDIT / Share (Rs.) | 7.14 | 5.04 | 8.34 | 14.58 | 18.03 |
| PBIT / Share (Rs.) | 2.57 | 0.80 | 4.54 | 11.15 | 15.49 |
| PBT / Share (Rs.) | -0.02 | -1.47 | 2.65 | 12.57 | 14.12 |
| Net Profit / Share (Rs.) | -0.34 | -1.26 | 1.81 | 8.85 | 11.60 |
| PBDIT Margin (%) | 11.60 | 9.41 | 12.22 | 14.83 | 27.82 |
| PBIT Margin (%) | 4.18 | 1.50 | 6.65 | 11.33 | 23.90 |
| PBT Margin (%) | -0.04 | -2.74 | 3.88 | 12.78 | 21.78 |
| Net Profit Margin (%) | -0.56 | -2.36 | 2.65 | 8.99 | 17.89 |
| Return on Networth / Equity (%) | -0.96 | -3.42 | 4.73 | 24.30 | 42.11 |
| Return on Capital Employeed (%) | 3.87 | 1.16 | 6.50 | 17.22 | 26.86 |
| Return On Assets (%) | -0.32 | -1.23 | 1.79 | 9.16 | 13.25 |
| Long Term Debt / Equity (X) | 0.73 | 0.75 | 0.71 | 0.67 | 1.07 |
| Total Debt / Equity (X) | 1.37 | 1.37 | 1.16 | 1.04 | 1.28 |
| Asset Turnover Ratio (%) | 0.59 | 0.52 | 0.69 | 1.07 | 0.89 |
| Current Ratio (X) | 0.46 | 0.53 | 0.60 | 0.68 | 0.65 |
| Quick Ratio (X) | 0.30 | 0.21 | 0.30 | 0.45 | 0.49 |
| Inventory Turnover Ratio (X) | 7.20 | 1.11 | 2.48 | 5.82 | 2.02 |
| Interest Coverage Ratio (X) | 2.75 | 2.22 | 4.41 | 9.33 | 13.16 |
| Interest Coverage Ratio (Post Tax) (X) | 0.86 | 0.44 | 1.96 | 4.75 | 9.46 |
| Enterprise Value (Cr.) | 25.47 | 23.72 | 19.75 | 16.16 | 0.00 |
| EV / Net Operating Revenue (X) | 1.35 | 1.44 | 0.94 | 0.53 | 0.00 |
| EV / EBITDA (X) | 11.62 | 15.33 | 7.71 | 3.61 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| Price / BV (X) | 0.95 | 0.72 | 0.52 | 0.49 | 0.00 |
| Price / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| EarningsYield | -0.01 | -0.04 | 0.09 | 0.48 | 0.00 |
After reviewing the key financial ratios for Chemiesynth (Vapi) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.22. This value is within the healthy range. It has increased from 2.97 (Mar 24) to 4.22, marking an increase of 1.25.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.52. It has increased from 53.53 (Mar 24) to 61.52, marking an increase of 7.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.14. This value is within the healthy range. It has increased from 5.04 (Mar 24) to 7.14, marking an increase of 2.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.57. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.57, marking an increase of 1.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 0. It has increased from -1.47 (Mar 24) to -0.02, marking an increase of 1.45.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.34. This value is below the healthy minimum of 2. It has increased from -1.26 (Mar 24) to -0.34, marking an increase of 0.92.
- For PBDIT Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 9.41 (Mar 24) to 11.60, marking an increase of 2.19.
- For PBIT Margin (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 10. It has increased from 1.50 (Mar 24) to 4.18, marking an increase of 2.68.
- For PBT Margin (%), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 10. It has increased from -2.74 (Mar 24) to -0.04, marking an increase of 2.70.
- For Net Profit Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 5. It has increased from -2.36 (Mar 24) to -0.56, marking an increase of 1.80.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.96. This value is below the healthy minimum of 15. It has increased from -3.42 (Mar 24) to -0.96, marking an increase of 2.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.87. This value is below the healthy minimum of 10. It has increased from 1.16 (Mar 24) to 3.87, marking an increase of 2.71.
- For Return On Assets (%), as of Mar 25, the value is -0.32. This value is below the healthy minimum of 5. It has increased from -1.23 (Mar 24) to -0.32, marking an increase of 0.91.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.73. This value is within the healthy range. It has decreased from 0.75 (Mar 24) to 0.73, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.37. This value exceeds the healthy maximum of 1. There is no change compared to the previous period (Mar 24) which recorded 1.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has increased from 0.52 (Mar 24) to 0.59, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1.5. It has decreased from 0.53 (Mar 24) to 0.46, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.30, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.20. This value is within the healthy range. It has increased from 1.11 (Mar 24) to 7.20, marking an increase of 6.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 3. It has increased from 2.22 (Mar 24) to 2.75, marking an increase of 0.53.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 3. It has increased from 0.44 (Mar 24) to 0.86, marking an increase of 0.42.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25.47. It has increased from 23.72 (Mar 24) to 25.47, marking an increase of 1.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.62. This value is within the healthy range. It has decreased from 15.33 (Mar 24) to 11.62, marking a decrease of 3.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has increased from 0.72 (Mar 24) to 0.95, marking an increase of 0.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to -0.01, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemiesynth (Vapi) Ltd:
- Net Profit Margin: -0.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.87% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.96% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 64.85)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.37
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | Plot No 27, GIDC, Phase-1 Vapi, Valsad District Gujarat 396195 | compliance@chemiesynth.com www.chemiesynth.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sandip Satishbhai Zaveri | Managing Director |
| Mr. Satish Bhogilal Zaveri | Non Exe.Non Ind.Director |
| Mr. Rushabh Suresh Mehta | Non Exe.Non Ind.Director |
| Mr. Pramod Gopaldas Gujarathi | Independent Director |
| Mrs. Jigna Prajapati | Independent Woman Director |
FAQ
What is the intrinsic value of Chemiesynth (Vapi) Ltd?
Chemiesynth (Vapi) Ltd's intrinsic value (as of 03 January 2026) is ₹3.97 which is 89.44% lower the current market price of ₹37.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹11.6 Cr. market cap, FY2025-2026 high/low of ₹37.6/35.8, reserves of ₹7.01 Cr, and liabilities of ₹32.56 Cr.
What is the Market Cap of Chemiesynth (Vapi) Ltd?
The Market Cap of Chemiesynth (Vapi) Ltd is 11.6 Cr..
What is the current Stock Price of Chemiesynth (Vapi) Ltd as on 03 January 2026?
The current stock price of Chemiesynth (Vapi) Ltd as on 03 January 2026 is ₹37.6.
What is the High / Low of Chemiesynth (Vapi) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemiesynth (Vapi) Ltd stocks is ₹37.6/35.8.
What is the Stock P/E of Chemiesynth (Vapi) Ltd?
The Stock P/E of Chemiesynth (Vapi) Ltd is .
What is the Book Value of Chemiesynth (Vapi) Ltd?
The Book Value of Chemiesynth (Vapi) Ltd is 32.8.
What is the Dividend Yield of Chemiesynth (Vapi) Ltd?
The Dividend Yield of Chemiesynth (Vapi) Ltd is 0.00 %.
What is the ROCE of Chemiesynth (Vapi) Ltd?
The ROCE of Chemiesynth (Vapi) Ltd is 3.10 %.
What is the ROE of Chemiesynth (Vapi) Ltd?
The ROE of Chemiesynth (Vapi) Ltd is 0.99 %.
What is the Face Value of Chemiesynth (Vapi) Ltd?
The Face Value of Chemiesynth (Vapi) Ltd is 10.0.